Biotech Values

[ThomasS]

MNTA: I think the "outlandish valuations" are actually pessimistic. They assume a modest P/S value; further, they do not ascribe any value to a potential Sandoz filing in EU.
I'm going out on a limb and suggesting that Sandoz files in EU the same month that MNTA files the immunogenicity supplement to the FDA. (They'll have a complete dossier to file.)